SUBSCRIBE
SUBSCRIBE
Genetown

Icahn, Eastbourne Put Pressure on Amylin Pharmaceuticals, Inc. Board

February 3, 2009 | 
1 min read

BOSTON, Feb. 2 (Reuters) - A battle looks set to break out for control of Amylin Pharmaceuticals Inc (AMLN.O), maker of the diabetes drug Byetta, as two big investors move to shake up the board.

MORE ON THIS TOPIC
Job Trends
Massachusetts’ Life Sciences Job Growth Slows, but 10-Year Outlook Remains Strong: Report
June 12, 2024
 · 
4 min read
 · 
Angela Gabriel
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Collage of Sarepta Therapeutics, DNA, and an IV bag
FDA
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
May 7, 2024
 · 
4 min read
 · 
Tyler Patchen